Process validation and preclinical development of a new PET cerebral blood flow tracer [11C]MMP for initial clinical trials
Abstract Background 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) is commonly used for diagnosis of dementia because brain glucose metabolism reflects neuronal activity. However, as [18F]FDG is an analogue of glucose, accumulation of tracer in the brain is affected by plasma glucose levels. In contrast...
Enregistré dans:
Auteurs principaux: | , , |
---|---|
Format: | Livre |
Publié: |
SpringerOpen,
2024-07-01T00:00:00Z.
|
Sujets: | |
Accès en ligne: | Connect to this object online. |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Internet
Connect to this object online.3rd Floor Main Library
Cote: |
A1234.567 |
---|---|
Exemplaire 1 | Disponible |